Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, Clemens SAC, Roa C Jr, Borja-Tabora C, Quinsaat A, Lopez P, López-Medina E, Brochado L, Hernández EA, Reynales H, Medina T, Velasquez H, Toloza LB, Rodriguez EJ, de Salazar DIM, Rodríguez CA, Sprinz E, Cerbino-Neto J, Luz KG, Schwarzbold AV, Paiva MS, Carlos J, Montellano MEB, de Los Reyes MRA, Yu CY, Alberto ER, Panaligan MM, Salvani-Bautista M, Buntinx E, Hites M, Martinot JB, Bhorat QE, Badat A, Baccarini C, Hu B, Jurgens J, Engelbrecht J, Ambrosino D, Richmond P, Siber G, Liang J, Clemens R. Bravo L, et al. Among authors: smolenov i. Lancet. 2022 Jan 29;399(10323):461-472. doi: 10.1016/S0140-6736(22)00055-1. Epub 2022 Jan 20. Lancet. 2022. PMID: 35065705 Free PMC article. Clinical Trial.
Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.
Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, Oostvogels LC, Suryakiran PV, Smolenov IV, Han HH, Bock HL. Phua KB, et al. Among authors: smolenov iv. Vaccine. 2009 Oct 9;27(43):5936-41. doi: 10.1016/j.vaccine.2009.07.098. Epub 2009 Aug 11. Vaccine. 2009. PMID: 19679216 Clinical Trial.
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Richmond P, et al. Among authors: smolenov i. Lancet. 2021 Feb 20;397(10275):682-694. doi: 10.1016/S0140-6736(21)00241-5. Epub 2021 Jan 29. Lancet. 2021. PMID: 33524311 Free PMC article. Clinical Trial.
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study.
Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, Vermeulen W, Verhoeven C, Leav B, Zhang B, Sawlwin D, Hamers-Heijnen E, Edelman J, Smolenov I. Beran J, et al. Among authors: smolenov i. Lancet Infect Dis. 2021 Jul;21(7):1027-1037. doi: 10.1016/S1473-3099(20)30694-0. Epub 2021 Feb 9. Lancet Infect Dis. 2021. PMID: 33577767 Clinical Trial.
Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine.
Richmond PC, Hatchuel L, Pacciarini F, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Richmond PC, et al. Among authors: smolenov i. J Infect Dis. 2021 Nov 22;224(10):1699-1706. doi: 10.1093/infdis/jiab447. J Infect Dis. 2021. PMID: 34480575 Free PMC article. Clinical Trial.
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Nolan T, Fortanier AC, Leav B, Põder A, Bravo LC, Szymański HT, Heeringa M, Vermeulen W, Matassa V, Smolenov I, Edelman JM. Nolan T, et al. Among authors: smolenov i. N Engl J Med. 2021 Oct 14;385(16):1485-1495. doi: 10.1056/NEJMoa2024848. N Engl J Med. 2021. PMID: 34644472 Clinical Trial.
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
Smolenov I, Han HH, Li P, Baccarini C, Verhoeven C, Rockhold F, Clemens SAC, Ambrosino D, Richmond P, Siber G, Liang J, Clemens R; SPECTRA Study Group. Smolenov I, et al. Lancet Infect Dis. 2022 Jul;22(7):990-1001. doi: 10.1016/S1473-3099(22)00144-X. Epub 2022 Apr 18. Lancet Infect Dis. 2022. PMID: 35447085 Free PMC article. Clinical Trial.
Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study.
Costa Clemens SA, Milan EP, Sprinz E, Neto JC, Pacciarini F, Li P, Chen HL, Smolenov I, Pollard A, Clemens R. Costa Clemens SA, et al. Among authors: smolenov i. Open Forum Infect Dis. 2022 Aug 16;9(8):ofac418. doi: 10.1093/ofid/ofac418. eCollection 2022 Aug. Open Forum Infect Dis. 2022. PMID: 36043184 Free PMC article.
48 results